Blue Horseshoe Stocks: The Week’s Top Winners

The Week’s Top Winners

Cisco Systems, Inc. CSCO – Among our fresh options ideas that we provided readers in yesterday’s premarket report, was a range of calls in the CSCO chain after the company issued much better Q1 figures than were expected.

Our targets were the CSCO Weekly $45-50-47.50 Calls and not only did they all produce instant opportunities for single-session profits, but those gains ended up being absolutely huge multi-bag intraday runs:

$45.50 Calls – Range: .40-1.33 – Max Gain: 232%
$46 Calls – Range: .20-.91 – Max Gain: 355%
$46.50 Calls – Range: .10-.54 – Max Gain: 440%
$47 Calls – Range: .03-.30 – Max Gain: 900%
$47.50 Calls – Range: .03-.11 – Max Gain: 266%
_____

We also had signled the Amarin Corp AMRN Weekly $15.50-17 Calls  and those too produced multi-bag rips across the board:

$15.50 Calls – Range: 1.22-3.90 – Max Gain: 220%
$16 Calls – Range: 1.00-3.00 – Max Gain: 200%
$16.50 Calls – Range: .69-2.90 – Max Gain: 320%
$17 Calls – Range: .52-2.00 – Max Gain: 285%

Today, we’ll look to potentially roll up our strike prices on AMRN to the Weekly $17 & $18 Calls*.

Bonus Idea:
PCG Weekly $24-26.50 Calls*

*NEVER trade weekly options on a Friday unless you are expert-level trader with disposable funds


Extended Watchlist:
NE, EOX, FPAY, ZAYO, AEZS, GSL, OGEN, SDRL

Blue Horseshoe Stocks: Kicking Off the Short Week

INSYS Therapeutics, Inc. INSY

This morning we kick off the holiday shortened week, during a time of year that typically sees subdued activity for the markets as a whole, as people spend time with their families, and stay busy with holiday festivities.

We still strive to identify possible opportunities even in this environment, and the first thing to hit our scanner this morning was INSY. INSYS Therapeutics recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy.

The FDA, we’re learning today, has also granted Fast Track status to INSY for the ‘drug’ for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder. (View PR)

The stock registered its 52-week lows at the beginning of last month, and has been in a general uptrend since, but we’ll be looking for further bullish activity on the heels of this FDA news, both on the stock chart, and in the options chain as a secondary idea. For that, we’ll look to the INSY 01/19 $8 & $9 Calls for opportunities.


DelMar Pharmaceuticals, Inc. DMPI

Speaking of FDA Fast Track designations, we’re looking to DMPI this morning as well, which was granted the status by the FDA for its lead-product cancer treatment, VAL-083.

The chart itself was already set up as a possible bottom play, and despite gapping up considerably on this morning’s news, there is still room to the upside, including a sizable gap that’s been left on the chart since this past spring, the eventual filling of which would spell gains of more than 100% from the current PPS.


Extended Watchlist:
KLXI, EXXI, AEZS, SRAX, IMUC, NETE

Blue Horseshoe Stocks: Updates, Bottom-Plays & More


Aeterna Zentaris, Inc. AEZS

We flagged AEZS on Wednesday’s morning, and saw rip its way to nearly a 90% gain. Then yesterday morning, we took note of the heavy volume and kept the stock on our radar.

It didn’t quite match the degree of the previous session’s move, but still followed it up with a solid performance, running from 2.55 to 3.29 on the day. That’s an intraday spike of 29% and a two-day upswing of 122% over our observed low of 1.48,  while volume was massive once again. We’ll be looking for AEZS to possibly continue its multi-day run, and would want to see maintain support at or above Wednesday’s closing price of 2.34 on any pullbacks, in order to remain interested.


ImmunoCellular Therapeutics, Ltd. IMUC

We want to radar IMUC as a bottom-watch play this morning. We noticed the stock had fallen to a new annual low yesterday, following the pricing of a public offering earlier this week, that is expected to be executed today.

We’re always on the lookout for battered stocks that could become rebound play candidates, and we’re always looking for charts with gaps to the upside and IMUC currently checks both of those boxes.


Extended Watchlist:
PPHM, OTTV, TVIA, OPGN, TXMD, FTR, MBRX, PLUG